A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 10, 2022

Primary Completion Date

September 15, 2022

Study Completion Date

September 15, 2022

Conditions
CoronavirusSARS-CoV-2 InfectionCOVID-19
Interventions
BIOLOGICAL

LD Vehicle-GNP

Two intradermal injections in the upper arm spaced 21 days apart

BIOLOGICAL

LD PepGNP-Covid19

Two intradermal injections in the upper arm spaced 21 days apart

BIOLOGICAL

HD Vehicle-GNP

Two intradermal injections in the upper arm spaced 21 days apart

BIOLOGICAL

HD PepGNP-Covid19

Two intradermal injections in the upper arm spaced 21 days apart

Trial Locations (1)

1004

Center for Primary Care and Public Health (Unisante), Lausanne

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

OTHER

collaborator

University of Lausanne Hospitals

OTHER

lead

Gylden Pharma Ltd

INDUSTRY